Is it suitable to eliminate bone scan for prostate cancer patients with PSA ≤ 20 ng/mL?

Lee, Seung Hwan; Chung, Mun Su; Park, Kyung Kgi; Yom, Chan Dong; Lee, Dae Hoon; Chung, Byung Ha

doi:10.1007/s00345-011-0728-6

Cited by 20 publications

(19 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similar findings were found in Pakistan, where there was an overall increased incidence of bone metastasis in newly diagnosed patients with prostate cancer and even at serum PSA level≤20 ng/ml and Gleason score <8 (Zaman et al, 2011). In Korea, 27 men (4.6%) with serum PSA between 10 and 20 ng/mL, 29/579 men (5.0%) with GS≤7, and 21/83 (25.3%) with serum PSA≤20 ng/mL and Gleason score (GS)≤7 had positive bone scans (Lee et al, 2012).…”

Section: Discussionmentioning

confidence: 99%

Retrospective Study of Predictors of Bone Metastasis in Prostate Cancer Cases

Seong

Zainuddin³

et al. 2013

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Retrospective Study of Predictors of Bone Metastasis in Prostate Cancer Cases

Seong

Zainuddin³

et al. 2013

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

“…The false-positive rate was higher in our study (20%) than in previous studies, 12,13 perhaps due to the higher percentage of patients with bone metastasis in our study. However, other studies have reported even higher percentages of bone metastasis, including studies by Al-Ghazo and colleagues 15 (98 patients, 39.7% had bone metastasis), Lai and colleagues 16 (116 patients, 29.3% with metastasis), Kosuda and colleagues 17 (1294 patients, 22% with metastasis), and Lee and colleagues 11 (579 patients, 14.3% with metastasis). Therefore, the percentage of bone metastasis in our study was not unusually high.…”

Section: Discussionmentioning

confidence: 91%

“…16 Lai and colleagues 16 suggested that guidelines for Asians might differ from those for Caucasians. Lee and colleagues 11 showed the need for a bone scan in patients with PSA values of 10 to 20 ng/mL and suggested that new guidelines might be needed for Asians. In our study of Korean patients, 16 (2% of total patients) had bone metastases, even though none of the 4 guidelines recommended a bone scan for them.…”

Section: Discussionmentioning

confidence: 99%

“…Additionally, current Western guidelines should be applied to Asian patients with caution. 10,11 Therefore, we evaluated the accuracy of the current guidelines by analyzing bone scan results and clinical parameters of patients with prostate cancer to determine the optimal guideline for predicting metastasis. Additionally, we examined the value of adding the percentage of positive biopsy core to predict bone metastasis.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Application of bone scans for prostate cancer staging: Which guideline shows better result?

Chong

Hwang

et al. 2014

CUAJ

View full text Add to dashboard Cite

Cite as: Can Urol Assoc J 2014;8(7-8):e515-9. http://dx.doi.org/10.5489/cuaj.2054 Published online August 11, 2014. AbstractIntroduction: We evaluated the accuracy of current guidelines by analyzing bone scan results and clinical parameters of patients with prostate cancer to determine the optimal guideline for predicting bone metastasis. Methods: We retrospectively analyzed patients who were diagnosed with prostate cancer and who underwent a bone scan. Bone metastasis was confirmed by bone scan results with clinical and radiological follow-up. Serum prostate-specific antigen, Gleason score, percent of positive biopsy core, clinical staging and bone scan results were analyzed. We analyzed diagnostic performance in predicting bone metastasis of the guidelines of the European Association of Urology (EAU), American Urological Association (AUA), and the National Comprehensive Cancer Network (NCCN) guidelines as well as Briganti's classification and regression tree (CART). We also compared the percent of positive biopsy core between patients with and without bone metastases. Results: A total 167 of 806 patients had bone metastases. Receiver operating curve analysis revealed that the AUA and EAU guidelines were better for detecting bone metastases than were Briganti's CART and NCCN. No significant difference was observed between AUA and EAU guidelines. Patients with bone metastases had a higher percent positive core than did patients without metastasis (the cut-off value >55.6). Conclusion:The EAU and AUA guidelines showed better results than did Briganti's CART and NCCN for predicting bone metastasis in the enrolled patients. A bone scan is strongly recommended for patients who have a higher percent positive core and who meet the EAU and AUA guidelines.

show abstract

“…In addition to the studies in which PSA and GS values are separately assessed to predict bone metastasis in PCa, there is also a number of studies in the literature in which both parameters are combined and the evaluation is made in this way, which is suggested to be more useful in predicting bone metastases (7,18,19).…”

Section: Discussionmentioning

confidence: 99%

Relationship Between Bone Scintigraphy Results and Gleason Scores and Prostate- Specific Antigen Levels

Şahin¹

2017

Istanbul Med J

View full text Add to dashboard Cite

Prostate cancer (PCa) is the most common non-cutaneous cancer in men, especially in the U.S. and European countries, although it is seen at various frequencies depending on genetic and regional differences (1, 2). Because the surgical treatment is the most effective method for localized PCa, accurate staging in patients is very important in terms of treatment and therefore survival morbidity. The most common distant metastasis in PCa is bone metastases, and the majority of them have osteoblastic characteristics, and they can be detected with high accuracy through the whole-body bone scintigraphy with the technetium 99 m-methylene diphosphonate (Tc99m-MDP). Although scintigraphic method has advantages such as high sensitivity and a full body scanning in one step; due to their low specificity and cost disadvantages, there is still no clear consensus in all countries to use it in staging before the treatment in newly diagnosed patients with prostate cancer. If the prostate-specific antigen (PSA) is ≤20 ng/mL, the Gleason score (GS) is ≤7, and the patient has no additional complaint, there is no need for scintigraphic imaging for bone metastasis according to the guidelines of prostate cancer of the American and European Urology associations; however the prostate cancer guideline of the Japanese Urology Association does not accept this view (3-5). While the National Comprehensive Cancer Network (NCNN) recommends bone scintigraphy in clinical T3, T4 stage patients or in patients with bone symptoms, it has the opinion that bone scintigraphy should be performed if the PSA value is above 10 ng/mL or GS value is 8 or above in patients with the stage of T1 or T2 (6). As can be understood from these, it is controversial in which cases bone scintigraphy should be used in patients with PCa diagnosis.We aimed to reveal the relationship between bone scintigraphy results and the levels of GS and PSA in terms of the determination of metastasis in patients with PCa and to provide information about the necessity of using bone scintigraphy according to the results obtained. MethodsIn our study, scintigraphic images and file records (anamnesis, physical examination, PSA, GS, and radiological examination results, if any) of male patients who were histopathologically diagnosed with PCa and who came to our hospital's nuclear medicine department for whole-body bone scin- Relationship Between Bone Scintigraphy Results and Gleason Scores and Prostate-Specific Antigen LevelsIntroduction: We aimed to determine the relationship between bone scintigraphy results and Gleason score (GS) and prostate-specific antigen (PSA) levels in the detection of bone metastases in patients diagnosed with prostate cancer. Further, the predictive values of PSA levels and GSs were determined using bone scintigraphy.Methods: Seventy-three patients diagnosed with prostate cancer and who underwent bone scintigraphy for staging at our department between 2013 and 2015 were enrolled. The records of these patients were retrospectively reviewed for determining bone scin...

show abstract

Is it suitable to eliminate bone scan for prostate cancer patients with PSA ≤ 20 ng/mL?

Cited by 20 publications

References 18 publications

Retrospective Study of Predictors of Bone Metastasis in Prostate Cancer Cases

Retrospective Study of Predictors of Bone Metastasis in Prostate Cancer Cases

Application of bone scans for prostate cancer staging: Which guideline shows better result?

Relationship Between Bone Scintigraphy Results and Gleason Scores and Prostate- Specific Antigen Levels

Contact Info

Product

Resources

About